1. Home
  2. NUVL vs VFC Comparison

NUVL vs VFC Comparison

Compare NUVL & VFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$105.83

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo V.F. Corporation

VFC

V.F. Corporation

HOLD

Current Price

$18.65

Market Cap

7.6B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
VFC
Founded
2017
1899
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
7.6B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NUVL
VFC
Price
$105.83
$18.65
Analyst Decision
Strong Buy
Hold
Analyst Count
15
16
Target Price
$135.00
$16.27
AVG Volume (30 Days)
548.0K
5.7M
Earning Date
02-26-2026
01-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.23
Revenue
N/A
$9,541,055,000.00
Revenue This Year
N/A
$0.12
Revenue Next Year
N/A
$0.84
P/E Ratio
N/A
$81.21
Revenue Growth
N/A
N/A
52 Week Low
$55.54
$9.41
52 Week High
$112.88
$29.02

Technical Indicators

Market Signals
Indicator
NUVL
VFC
Relative Strength Index (RSI) 54.70 48.94
Support Level $97.43 $19.01
Resistance Level $108.65 $20.50
Average True Range (ATR) 4.95 0.71
MACD 0.48 -0.13
Stochastic Oscillator 82.96 27.50

Price Performance

Historical Comparison
NUVL
VFC

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About VFC V.F. Corporation

VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 10 brands includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.

Share on Social Networks: